Showing 961 - 980 results of 49,663 for search '(( 50 ((na decrease) OR (((mean decrease) OR (a decrease)))) ) OR ( 12 m decrease ))', query time: 1.14s Refine Results
  1. 961
  2. 962
  3. 963
  4. 964
  5. 965
  6. 966
  7. 967
  8. 968
  9. 969

    Elevated IDO activity in HD mouse brains is decreased by <i>ex-vivo</i> iron chelation. by David W. Donley (3111198)

    Published 2021
    “…<p>Mouse pups were supplemented with carbonyl iron from postnatal days 10–17 and then were sacrificed at 14 weeks of age. <b>A.</b> Striatal IDO activity is increased in N171-82Q HD mice and significantly decreased by <i>ex vivo</i> iron (III) chelation (50 μM deferoxamine). …”
  10. 970
  11. 971
  12. 972
  13. 973
  14. 974
  15. 975

    Time-course of changes induced on NCAM and SYN synaptic patterns and levels by glutamate exposure. by María Fernanda Podestá (639243)

    Published 2014
    “…<p>Hippocampal neurons in culture (DIV 12–13) were briefly exposed to 5 µM glutamate and evaluated 1, 3, 6 and 12 h later. …”
  16. 976

    Early surface PSA-NCAM reduction induced by glutamate exposure. by María Fernanda Podestá (639243)

    Published 2014
    “…<p>Hippocampal neurons in culture (DIV 12–13) were briefly exposed to 5 µM glutamate and evaluated 1, 3 and 6 h later. …”
  17. 977

    Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study by Jon Jarløv Rasmussen (2993427)

    Published 2016
    “…</p><p>Methods</p><p>This study had a cross-sectional case-control design and involved 37 current AAS abusers, 33 former AAS abusers (mean (95%CI) elapsed duration since AAS cessation: 2.5 (1.7; 3.7) years) and 30 healthy control participants. …”
  18. 978
  19. 979

    Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  20. 980

    Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”